COXIBRAIN: results of the prospective, randomised, phase II/III study for the selective COX-2 inhibition in chronic subdural haematoma patients

详细信息    查看全文

• 作者：A. Schaumann ; W. Klene ; Chr. Rosenstengel ; F. Ringel ; J. Tüttenberg…
• 关键词：Chronic subdural haematoma ; Selective COX ; 2 inhibition ; Anti ; angiogenic treatment ; COXIBRAIN study
• 刊名：Acta Neurochirurgica
• 出版年：2016
• 出版时间：November 2016
• 年：2016
• 卷：158
• 期：11
• 页码：2039-2044
• 全文大小：484 KB
• 刊物主题：Neurosurgery; Interventional Radiology; Neuroradiology; Neurology; Surgical Orthopedics; Minimally Invasive Surgery;
• 出版者：Springer Vienna
• ISSN：0942-0940
• 卷排序：158

文摘

BackgroundChronic subdural haematomas (cSDHs) have shown an increasing incidence in an ageing population over the last 20 years, while unacceptable recurrence rates of up to 30 % persist. The recurrence rate of cSDH seems to be related to the excessive neoangiogenesis in the parietal membrane, which is mediated via vascular endothelial growth factor (VEGF). This is found to be elevated in the haematoma fluid and is dependent on eicosanoid/prostaglandin and thromboxane synthesis via cyclo-oxygenase-2 (COX-2). With this investigator-initiated trial (IIT) it was thought to diminish the recurrence rate of operated-on cSDHs by administering a selective COX-2 inhibitor (Celecoxib) over 4 weeks’ time postoperatively in comparison to a control group.